Skip to content
by Legal Desire
7 October 2023

Linklaters advises Theramex (a portfolio company of PAI Partners and Carlyle) on Theramex’s proposed acquisition of Duphaston and Femoston oral menopause drugs from Viatris

Advising firms

Deal team

20 lawyers named
LawyerFirmSeniorityPracticeOffice
Daniel Law Lead Linklaters Partner Corporate London
Alex Woodward Lead Linklaters Partner Corporate London
Marly Didizian Lead Linklaters Partner Commercial (Carve-Out) London
Yohan Liyanage Lead Linklaters Partner IP London
Jamie Coomber Lead Linklaters Partner Tax London
Alex Selig Linklaters Not stated Corporate London
Kaiya Kim-Saville Linklaters Associate Corporate London
Asim Ayub Linklaters Associate Corporate London
Tibi Sandu Linklaters Associate Corporate London
Catherine Yuen Linklaters Associate Corporate New York
James Marlow Linklaters Not stated ESG London
Danny Greenland Linklaters Associate Commercial (Carve-Out) London
Rachel Varnam Linklaters Associate Commercial (Carve-Out) London
Stephanie Farrington Linklaters Not stated IP London
Olivia Williams Linklaters Associate IP London
Neil Hoolihan Linklaters Partner Antitrust Brussels
Jonathan Ford Linklaters Partner Antitrust London
Juliane Guderian Linklaters Not stated Antitrust London
Sebastian Plötz Linklaters Not stated Antitrust Düsseldorf
Rohesia Vince Linklaters Associate Tax London

Stated terms

Stated value
Not stated
What the figure measures
Not stated
Client
TheramexBuy-side
Counterparties
Viatris, Inc. (Sell-side)